A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: Result of a phase Ia clinical trial

被引：0

作者：

Shen, L. ^{[1
]}

Gong, J. ^{[1
]}

Xu, Y. ^{[1
]}

Zhang, X. ^{[1
]}

Peng, Z. ^{[1
]}

Qi, C. ^{[1
]}

Li, G. ^{[2
]}

Meng, H. ^{[2
]}

Liu, Z. ^{[2
]}

Wang, H. ^{[2
]}

Chen, C. ^{[3
]}

Li, J. ^{[3
]}

Zheng, Y. ^{[3
]}

Lee, J. ^{[4
]}

Zhang, Y. ^{[4
]}

Zhang, Q. ^{[4
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China

[2] Guangzhou Gloria Biosci Co Ltd, Gloria Biosci, Beijing, Peoples R China

[3] WuXi Biol Shanghai Co Ltd, WuXi Biol, Shanghai, Peoples R China

[4] Wuxi Clin Dev Serv Shanghai Co Ltd, Wuxi Clin, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

65P

引用

页数：2

共 50 条

[1] Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
Lou, Beilei
Wei, Hua
Yang, Fang
Wang, Shicong
Yang, Baotian
Zheng, Yong
Zhu, Jiman
Yan, Shaoyu
FRONTIERS IN ONCOLOGY, 2021, 11
[2] GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial
Shen, Lin
Gong, Jifang
Song, Yuqin
Ye, Dingwei
Lu, Zhihao
Wang, Siyang
Peng, Peijian
Chen, Jianhua
Jiang, Ou
Zhang, Guojun
Bai, Yuxian
Pan, Jianji
Ma, Chunguang
Chen, Li
Ba, Yi
Li, Qi
Lu, Ping
Zhang, Lingli
Yin, Xianli
Gu, Shanzhi
Zhang, Huilai
Su, Hang
Jiang, Yongsheng
Cao, Bangwei
Han, Weiqing
Sun, Yan
Zhang, Feng
Ouyang, Weiwei
Dong, Haiying
Guo, Jianming
Guo, Yabing
Xu, Chongyuan
Qi, Junyuan
Wang, Li
Lv, Jun
Wang, Xiang
Chen, Chris
Li, Jing
Zheng, Yong
Jin, Ge
Yang, Yining
Zhao, Guodong
Yang, Fan
Xu, Kehui
Liang, Xiangying
Pan, Zhaoyang
Meng, Haijin
CANCER RESEARCH, 2020, 80 (16)
[3] Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.
Song, Yuqin
Zhu, Jun
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin's lymphoma: Preliminary result of a phase II clinical trial.
Song, Yuqin
Zhu, Jun
Lin, Ningning
Zhang, Chen
Zhang, Mingzhi
Bai, Hai
Cui, Jie
Liu, Hui
Ke, Xiaoyan
Jiang, Yongsheng
Zhang, Zhihui
Zhang, Ying
Liu, Lihong
Zang, Aimin
Chen, Chris
Li, Jing
Du, Hong
Meng, Baotong
Xu, Kehui
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
Song, Yuqin
Zhu, Jun
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Meng, Haijin
BLOOD, 2020, 136
[6] Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody
Tan, Joanne B.
Chen, Chris
Chen, Kai
Li, Guochun
Li, Jing
Liu, Jieying
Singh, Hema
Wang, Guoyong
Yang, Baotian
Zhang, Kristin
Zhao, Xiaoning
Zheng, Yong
CANCER RESEARCH, 2018, 78 (13)
[7] Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Liu, Dan
Ma, Chunguang
Lu, Ping
Gong, Jifang
Ye, Dingwei
Wang, Siyang
Peng, Peijian
Bai, Yuxian
Song, Yuqin
Chen, Jianhua
Jiang, Ou
Zhang, Guojun
Ba, Yi
Chen, Li
Pan, Jianji
Li, Qi
Zhang, Liling
Gu, Shanzhi
Yin, Xianli
Cao, Bangwei
Han, Weiqing
Dong, Haiying
Guo, Jianming
Zhang, Huilai
Su, Hang
Jiang, Yongsheng
Ouyang, Weiwei
Ma, Lulin
Sun, Yan
Zhang, Feng
Lv, Jun
Guo, Yabing
Xu, Chongyuan
Qi, Junyuan
Wang, Li
Wang, Xiang
Liu, Zhen
Shen, Lin
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 1 - 13
[8] GLS-010 (ZIMBERELIMAB), A NOVEL FULLY HUMAN ANTI-PD-1 MAB IN CHINESE PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER: RESULTS FROM A MULTICENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL
Wu, X.
Xia, L.
Zhou, Q.
Zhu, J.
Wang, K.
Chen, J.
Huang, Y.
Kurb, G.
Chang, B.
Zhao, W.
Wang, X.
Yang, Y.
Lin, Z.
Luo, X.
Lou, G.
Wang, C.
Wang, J.
Meng, H.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A147 - A147
[9] Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Wu, Xiaohua
Xia, Lingfang
Zhou, Qi
Zhu, Jianqing
Wang, Ke
Chen, Jie
Huang, Yi
Kurb, Gulina
Chang, Baoping
Zhao, Weidong
Wang, Xia
Yang, Yingjie
Lin, Zhongqiu
Luo, Xiaoyong
Lou, Ge
Wang, Chunyan
Wang, Jing
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] G1s-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: Result of a phase Ib clinical trial.
Lin, Shen
Gong, Jifang
Xu, Yingying
Zhang, Xiaotian
Peng, Zhi
Qi, Changsong
Li, Guochun
Meng, Haijin
Liu, Zhen
Wang, Hui
Chen, Chris
Li, Jing
Zheng, Yong
Lee, Johnathan
Zhang, Yan
Zhang, Qiang
Jin, Ge
Yang, Yining
Zhao, Guodong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →